The business model of Evolus Inc. revolves around developing and commercializing prescription aesthetic products for healthcare professionals and their patients. Evolus primarily focuses on providing innovative products for facial aesthetics, with a key emphasis on its flagship brand, Jeuveau®. Jeuveau® is a prescription medicine that is injected into facial muscles to temporarily improve the appearance of moderate to severe glabellar lines (frown lines between the eyebrows). By offering safe and effective aesthetic solutions, Evolus Inc. aims to meet the growing demand for non-surgical treatments and contribute to the success of healthcare professionals and the satisfaction of their patients.

Evolus Inc is primarily active in the pharmaceutical and healthcare industries.

The main competitors of Evolus Inc in the market are major players in the medical aesthetics industry, including Allergan plc and Merz Pharma Group. These companies also manufacture and distribute aesthetic treatments and products, such as Botox and dermal fillers, which compete with Evolus' Jeuveau. Allergan, as a subsidiary of AbbVie Inc, remains a strong competitor in this segment, given its well-established brand reputation and extensive customer base. On the other hand, Merz Pharma Group, a global leader in the aesthetics market, offers its own range of injectable aesthetic products and medical devices, posing a competitive challenge to Evolus Inc.

Evolus Inc is a renowned pharmaceutical company specializing in aesthetic medicine. Established in 2012, Evolus has quickly made a name for itself in the industry. The company is focused on developing and commercializing innovative products for aesthetic procedures, with a primary emphasis on neurotoxins. Evolus is widely recognized for its flagship product Jeuveau™, a revolutionary wrinkle treatment approved by the FDA. Jeuveau™ competes directly with other well-known aesthetic brands, providing consumers with a broader range of choices. With a strong commitment to excellence and continuous innovation, Evolus Inc has emerged as a key player in the field of aesthetics.

Evolus Inc has achieved several significant milestones. Firstly, the company received FDA approval in 2019 for its revolutionary product Jeuveau, a wrinkle treatment. This approval marked a major breakthrough for Evolus Inc, as it became the first and only neurotoxin alternative to Botox in the United States. Additionally, the company successfully secured a collaboration agreement with Daewoong Pharmaceutical to commercialize Jeuveau in key Asian markets, further expanding its global reach. Evolus Inc's continuous efforts in research and development have enabled it to provide innovative aesthetic solutions, positioning the company as a leader in the industry.

Evolus Inc primarily operates in the United States.

Evolus Inc represents a commitment to innovation, integrity, and patient satisfaction. As a pharmaceutical company specializing in aesthetic medicine, Evolus aims to provide advanced solutions that enhance the lives of patients. The company values scientific excellence and invests in rigorous research and development to deliver high-quality products. With a customer-centric approach, Evolus fosters meaningful relationships with healthcare professionals and strives to meet the evolving needs of patients worldwide.

Analysts currently set an average price target of 16.83 USD for the Evolus stock (median: 18.36 USD), implying +180.0 % versus the latest price. The consensus is based on 13 analyst ratings.

Evolus Analyst Price Targets 2026

13 analysts currently rate the Evolus stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Evolus to generate revenue of 330.45 M USD and earnings per share of -0.09 USD.

Evolus Analyst Price Targets 2026

Converted at the current exchange rate, the Evolus share trades at 5.07 EUR (5.84 USD).

The Evolus share (EOLS) is listed on 6 stock exchanges, including: NASDAQ (EOLS), Frankfurt (EVL.F), München (EVL.MU), Düsseldorf (EVL.DU), London (0K16.L), London (0K16.L).

Evolus Inc is an American company based in California that specializes in the development, manufacturing, and marketing of prescription dermatological products. The business model primarily focuses on selling products and services in the beauty and aesthetic medicine fields, with a focus on developing technologies that naturally enhance the appearance of skin and face. Evolus Inc offers a wide range of products and services. In 2019, the company introduced its first and only product so far, Jeuveau, to the market. Jeuveau is an injectable botulinum toxin primarily used for treating glabellar lines or "frown lines" between the eyebrows. It is a cost-effective and effective alternative to the botulinum toxin preparations already available on the market. Recently, Evolus has also focused on other products and technologies to expand its offering. One such technology is the Heatwave technology, which provides a non-invasive way to stimulate collagen production in the face. It uses targeted heat energy to tighten the skin, reduce wrinkles, and overall improve the appearance of the face. Evolus Inc has also partnered with Kalos Therapeutics to develop a broader range of products for aesthetic dermatological therapy. This partnership includes the development of drug combinations that specifically target the causes of acne, rosacea, and other skin conditions. In terms of marketing and sales, Evolus primarily relies on direct sales. The products are sold on the company's website and in selected medical facilities. An important target audience are doctors, plastic surgeons, and dermatologists, to whom the company offers training and education to ensure the proper use of the products. In summary, Evolus Inc's business model is primarily based on the development and marketing of innovative skincare products and aesthetic procedures for the beauty industry. The company aims to develop cost-effective and effective alternatives to the products already available on the market and expand its presence in the industry. With its wide range of products and technologies and its focus on direct distribution channels, Evolus is well positioned to continue attracting the interest of customers and investors.

The expected revenue of Evolus is 330.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Evolus is -5.49 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Evolus is currently -68.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Evolus stock.

The price-to-sales ratio (P/S) of Evolus is currently 1.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Evolus stock.

The Eulerpool Quality Score for Evolus is 4/10.

The ISIN of Evolus is US30052C1071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Evolus is A2JDYX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Evolus is EOLS. The ticker symbol is used to trade Evolus shares on the stock exchange.

Evolus paid dividends every year for the past 0 years.

Evolus is assigned to the 'Health' sector.

The dividends of Evolus are distributed in USD.